Chromosome Disorders  >>  beloranib (ZGN-440)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beloranib (ZGN-440) / Larimar Therap
NCT01818921: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Checkmark
Jan 2014 - Jan 2014: 
Completed
2a
17
US
ZGN-440 sterile diluent, Placebo, 1.2 mg ZGN-440 for injectable suspension, ZGN-440 for injectable suspension, ZGN-440, ZGN-433, Beloranib, 1.8 mg ZGN-440 for injectable suspension
Zafgen, Inc.
Obesity, Over-weight, Prader-Willi Syndrome
11/13
11/13

Download Options